2024-11-252025-11-302025-11-30false16100622AS PHARMA CONSULTING LTD2026-08-18falseiso4217:GBPxbrli:pure161006222024-11-24161006222025-11-30161006222024-11-252025-11-30161006222024-11-23161006222024-11-24161006222024-11-242024-11-2416100622bus:SmallEntities2024-11-252025-11-3016100622bus:AuditExempt-NoAccountantsReport2024-11-252025-11-3016100622bus:FullAccounts2024-11-252025-11-3016100622bus:PrivateLimitedCompanyLtd2024-11-252025-11-3016100622core:WithinOneYear2025-11-3016100622core:AfterOneYear2025-11-3016100622core:WithinOneYear2024-11-2416100622core:AfterOneYear2024-11-2416100622core:ShareCapital2025-11-3016100622core:SharePremium2025-11-3016100622core:RevaluationReserve2025-11-3016100622core:OtherReservesSubtotal2025-11-3016100622core:RetainedEarningsAccumulatedLosses2025-11-3016100622core:ShareCapital2024-11-2416100622core:SharePremium2024-11-2416100622core:RevaluationReserve2024-11-2416100622core:OtherReservesSubtotal2024-11-2416100622core:RetainedEarningsAccumulatedLosses2024-11-2416100622core:LandBuildings2025-11-3016100622core:PlantMachinery2025-11-3016100622core:Vehicles2025-11-3016100622core:FurnitureFittings2025-11-3016100622core:OfficeEquipment2025-11-3016100622core:NetGoodwill2025-11-3016100622core:IntangibleAssetsOtherThanGoodwill2025-11-3016100622core:ListedExchangeTraded2025-11-3016100622core:UnlistedNon-exchangeTraded2025-11-3016100622core:LandBuildings2024-11-2416100622core:PlantMachinery2024-11-2416100622core:Vehicles2024-11-2416100622core:FurnitureFittings2024-11-2416100622core:OfficeEquipment2024-11-2416100622core:NetGoodwill2024-11-2416100622core:IntangibleAssetsOtherThanGoodwill2024-11-2416100622core:ListedExchangeTraded2024-11-2416100622core:UnlistedNon-exchangeTraded2024-11-2416100622core:LandBuildings2024-11-252025-11-3016100622core:PlantMachinery2024-11-252025-11-3016100622core:Vehicles2024-11-252025-11-3016100622core:FurnitureFittings2024-11-252025-11-3016100622core:OfficeEquipment2024-11-252025-11-3016100622core:NetGoodwill2024-11-252025-11-3016100622core:IntangibleAssetsOtherThanGoodwill2024-11-252025-11-3016100622core:ListedExchangeTraded2024-11-252025-11-3016100622core:UnlistedNon-exchangeTraded2024-11-252025-11-3016100622core:MoreThanFiveYears2024-11-252025-11-3016100622core:Non-currentFinancialInstruments2025-11-3016100622core:Non-currentFinancialInstruments2024-11-2416100622dpl:CostSales2024-11-252025-11-3016100622dpl:DistributionCosts2024-11-252025-11-3016100622core:LandBuildings2024-11-252025-11-3016100622core:PlantMachinery2024-11-252025-11-3016100622core:Vehicles2024-11-252025-11-3016100622core:FurnitureFittings2024-11-252025-11-3016100622core:OfficeEquipment2024-11-252025-11-3016100622dpl:AdministrativeExpenses2024-11-252025-11-3016100622core:NetGoodwill2024-11-252025-11-3016100622core:IntangibleAssetsOtherThanGoodwill2024-11-252025-11-3016100622dpl:GroupUndertakings2024-11-252025-11-3016100622dpl:ParticipatingInterests2024-11-252025-11-3016100622dpl:GroupUndertakingscore:ListedExchangeTraded2024-11-252025-11-3016100622core:ListedExchangeTraded2024-11-252025-11-3016100622dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-11-252025-11-3016100622core:UnlistedNon-exchangeTraded2024-11-252025-11-3016100622dpl:CostSales2024-11-242024-11-2416100622dpl:DistributionCosts2024-11-242024-11-2416100622core:LandBuildings2024-11-242024-11-2416100622core:PlantMachinery2024-11-242024-11-2416100622core:Vehicles2024-11-242024-11-2416100622core:FurnitureFittings2024-11-242024-11-2416100622core:OfficeEquipment2024-11-242024-11-2416100622dpl:AdministrativeExpenses2024-11-242024-11-2416100622core:NetGoodwill2024-11-242024-11-2416100622core:IntangibleAssetsOtherThanGoodwill2024-11-242024-11-2416100622dpl:GroupUndertakings2024-11-242024-11-2416100622dpl:ParticipatingInterests2024-11-242024-11-2416100622dpl:GroupUndertakingscore:ListedExchangeTraded2024-11-242024-11-2416100622core:ListedExchangeTraded2024-11-242024-11-2416100622dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-11-242024-11-2416100622core:UnlistedNon-exchangeTraded2024-11-242024-11-2416100622core:NetGoodwill2025-11-3016100622core:IntangibleAssetsOtherThanGoodwill2025-11-3016100622core:LandBuildings2025-11-3016100622core:PlantMachinery2025-11-3016100622core:Vehicles2025-11-3016100622core:FurnitureFittings2025-11-3016100622core:OfficeEquipment2025-11-3016100622core:AfterOneYear2025-11-3016100622core:WithinOneYear2025-11-3016100622core:ListedExchangeTraded2025-11-3016100622core:UnlistedNon-exchangeTraded2025-11-3016100622core:ShareCapital2025-11-3016100622core:SharePremium2025-11-3016100622core:RevaluationReserve2025-11-3016100622core:OtherReservesSubtotal2025-11-3016100622core:RetainedEarningsAccumulatedLosses2025-11-3016100622core:NetGoodwill2024-11-2416100622core:IntangibleAssetsOtherThanGoodwill2024-11-2416100622core:LandBuildings2024-11-2416100622core:PlantMachinery2024-11-2416100622core:Vehicles2024-11-2416100622core:FurnitureFittings2024-11-2416100622core:OfficeEquipment2024-11-2416100622core:AfterOneYear2024-11-2416100622core:WithinOneYear2024-11-2416100622core:ListedExchangeTraded2024-11-2416100622core:UnlistedNon-exchangeTraded2024-11-2416100622core:ShareCapital2024-11-2416100622core:SharePremium2024-11-2416100622core:RevaluationReserve2024-11-2416100622core:OtherReservesSubtotal2024-11-2416100622core:RetainedEarningsAccumulatedLosses2024-11-2416100622core:NetGoodwill2024-11-2316100622core:IntangibleAssetsOtherThanGoodwill2024-11-2316100622core:LandBuildings2024-11-2316100622core:PlantMachinery2024-11-2316100622core:Vehicles2024-11-2316100622core:FurnitureFittings2024-11-2316100622core:OfficeEquipment2024-11-2316100622core:AfterOneYear2024-11-2316100622core:WithinOneYear2024-11-2316100622core:ListedExchangeTraded2024-11-2316100622core:UnlistedNon-exchangeTraded2024-11-2316100622core:ShareCapital2024-11-2316100622core:SharePremium2024-11-2316100622core:RevaluationReserve2024-11-2316100622core:OtherReservesSubtotal2024-11-2316100622core:RetainedEarningsAccumulatedLosses2024-11-2316100622core:AfterOneYear2024-11-252025-11-3016100622core:WithinOneYear2024-11-252025-11-3016100622core:Non-currentFinancialInstrumentscore:CostValuation2024-11-252025-11-3016100622core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-11-252025-11-3016100622core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-11-252025-11-3016100622core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-11-252025-11-3016100622core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-11-252025-11-3016100622core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-11-252025-11-3016100622core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-11-252025-11-3016100622core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-11-252025-11-3016100622core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-11-252025-11-3016100622core:Non-currentFinancialInstrumentscore:CostValuation2025-11-3016100622core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-11-3016100622core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-11-3016100622core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-11-3016100622core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-11-3016100622core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-11-3016100622core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-11-3016100622core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-11-3016100622core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-11-3016100622core:Non-currentFinancialInstrumentscore:CostValuation2024-11-2416100622core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-11-2416100622core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-11-2416100622core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-11-2416100622core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-11-2416100622core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-11-2416100622core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-11-2416100622core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-11-2416100622core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-11-2416100622bus:Director12024-11-252025-11-30

AS PHARMA CONSULTING LTD

Registered Number
16100622
(England and Wales)

Unaudited Financial Statements for the Period ended
30 November 2025

AS PHARMA CONSULTING LTD
Company Information
for the period from 25 November 2024 to 30 November 2025

Director

SIPITANOU, Anna

Registered Address

34 Northwold Avenue
Nottingham
NG2 7JD

Registered Number

16100622 (England and Wales)
AS PHARMA CONSULTING LTD
Balance Sheet as at
30 November 2025

Notes

2025

£

£

Current assets
Debtors315,650
Cash at bank and on hand28,578
44,228
Creditors amounts falling due within one year4(19,939)
Net current assets (liabilities)24,289
Total assets less current liabilities24,289
Net assets24,289
Capital and reserves
Called up share capital1
Profit and loss account24,288
Shareholders' funds24,289
The financial statements were approved and authorised for issue by the Director on 18 August 2026, and are signed on its behalf by:
SIPITANOU, Anna
Director
Registered Company No. 16100622
AS PHARMA CONSULTING LTD
Notes to the Financial Statements
for the period ended 30 November 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
Related parties
For the purposes of these financial statements, a related party could be a person or an entity. Careful consideration is given to the definition of a related party to ensure that all related party relationships, transactions and balances are identified.
2.Average number of employees

2025
Average number of employees during the year1
3.Debtors: amounts due within one year

2025

£
Trade debtors / trade receivables15,650
Total15,650
4.Creditors: amounts due within one year

2025

£
Amounts owed to related parties12,564
Taxation and social security6,021
Accrued liabilities and deferred income1,354
Total19,939
5.Related party transactions
During the year interest free loans were made available to the business by directors of £12,564.